Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Cartesian Therapeutics (NASDAQ:RNAC) and maintained a $42 price target.
July 08, 2024 | 9:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on Cartesian Therapeutics (NASDAQ:RNAC) and maintained a $42 price target.
The reiteration of a Buy rating and the maintenance of a $42 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100